$0.96
1.07%
Nasdaq, Jul 03, 10:14 pm CET
ISIN
US09074F2074
Symbol
BIVI
Sector
Industry

BioVie Inc Stock price

$0.96
-0.13 11.93% 1M
-1.27 56.95% 6M
-1.04 52.00% YTD
-3.20 76.91% 1Y
-12.84 93.04% 3Y
-138.94 99.31% 5Y
-311.54 99.69% 10Y
-374.04 99.74% 20Y
Nasdaq, Closing price Fri, Jul 04 2025
+0.00 0.00%
ISIN
US09074F2074
Symbol
BIVI
Sector
Industry

Key metrics

Basic
Market capitalization
$17.8m
Enterprise Value
$-5.3m
Net debt
positive
Cash
$23.2m
Shares outstanding
18.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.8
Financial Health
Equity Ratio
61.5%
Return on Equity
-212.8%
ROCE
-85.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-18.7m | -
EBIT
$-18.9m | $-34.9m
Net Income
$-19.4m | $-83.3m
Free Cash Flow
$-17.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
50.9% | -
EBIT
50.7%
Net Income
47.9% | -152.5%
Free Cash Flow
50.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.0
FCF per Share
$-0.9
Short interest
7.6%
Employees
14
Rev per Employee
$0.0
Show more

Is BioVie Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

BioVie Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a BioVie Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a BioVie Inc forecast:

Buy
86%
Hold
14%

Financial data from BioVie Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.62 8.62
2% 2%
-
- Research and Development Expense 10 10
66% 66%
-
-19 -19
51% 51%
-
- Depreciation and Amortization 0.23 0.23
4% 4%
-
EBIT (Operating Income) EBIT -19 -19
51% 51%
-
Net Profit -19 -19
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about BioVie Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioVie Inc Stock News

Neutral
GlobeNewsWire
11 days ago
Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation
Neutral
GlobeNewsWire
12 days ago
CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial ...
Neutral
GlobeNewsWire
about 2 months ago
CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University ...
More BioVie Inc News

Company Profile

BioVie, Inc. is a development stage biopharmaceutical company, which discovers, develops, and commercializes drug therapies for liver disease. It focuses on BIV201 which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.

Head office United States
CEO Cuong Do
Employees 14
Founded 2013
Website www.bioviepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today